About this Special Issue
According to the World Health Organization (WHO), to date, there have been almost 800 million cases of Coronavirus Disease 2019 (COVID-19) and over 7 million deaths worldwide. The main causes of death are attributable to acute respiratory syndrome with cytokine storm, the cardiovascular complications of the disease, primarily coagulation disorders, and the transient immunodeficiency induced by the virus, which can also lead to the life-threatening reactivation of pathogens already present in the host organism. Among these pathogens, there are oncoviruses that exploit the state of immunocompromise to fully exert their oncogenic power. Furthermore, in 50-70% of hospitalized survivors and in 10-30% of non-hospitalized patients, long-COVID occurs, both for the sequelae of the infection and for the alterations into the pathway of the angiotensin-converting enzyme (ACE).
This Special Issue welcomes contributions that improve our understanding about COVID-19 and long-COVID both from a histological and oncological point of view, with clinicopathological correlations.
Potential areas of interest may include, but are not limited to:
● Cardiovascular pathology
● Pulmonary pathology
● Immunopathology
● Hematopathology
● Renal pathology
● Medical virology
● Medical oncology
Even though abstract submission is not mandatory, we encourage all interested researchers to submit an abstract before submitting their manuscript. Abstracts do not have to coincide with the final abstract of the manuscripts. For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: por@por-journal.com.
This Special Issue welcomes contributions that improve our understanding about COVID-19 and long-COVID both from a histological and oncological point of view, with clinicopathological correlations.
Potential areas of interest may include, but are not limited to:
● Cardiovascular pathology
● Pulmonary pathology
● Immunopathology
● Hematopathology
● Renal pathology
● Medical virology
● Medical oncology
Even though abstract submission is not mandatory, we encourage all interested researchers to submit an abstract before submitting their manuscript. Abstracts do not have to coincide with the final abstract of the manuscripts. For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: por@por-journal.com.
Keywords: COVID-19, long-COVID, SARS-CoV-2, Pathology, Oncology
